» Articles » PMID: 27821478

MCL-1 Depletion Impairs DNA Double-Strand Break Repair and Reinitiation of Stalled DNA Replication Forks

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2016 Nov 9
PMID 27821478
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid cell leukemia 1 (MCL-1) is a prosurvival BCL-2 protein family member highly expressed in hematopoietic stem cells (HSCs) and regulated by growth factor signals that manifest antiapoptotic activity. Here we report that depletion of MCL-1 but not its isoform MCL-1S increases genomic instability and cell sensitivity to ionizing radiation (IR)-induced death. MCL-1 association with genomic DNA increased postirradiation, and the protein colocalized with 53BP1 foci. Postirradiation, MCL-1-depleted cells exhibited decreased γ-H2AX foci, decreased phosphorylation of ATR, and higher levels of residual 53BP1 and RIF1 foci, suggesting that DNA double-strand break (DSB) repair by homologous recombination (HR) was compromised. Consistent with this model, MCL-1-depleted cells had a reduced frequency of IR-induced BRCA1, RPA, and Rad51 focus formation, decreased DNA end resection, and decreased HR repair in the DR-GFP DSB repair model. Similarly, after HU induction of stalled replication forks in MCL-1-depleted cells, there was a decreased ability to subsequently restart DNA synthesis, which is normally dependent upon HR-mediated resolution of collapsed forks. Therefore, the present data support a model whereby MCL-1 depletion increases 53BP1 and RIF1 colocalization at DSBs, which inhibits BRCA1 recruitment, and sensitizes cells to DSBs from IR or stalled replication forks that require HR for repair.

Citing Articles

Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents.

Lee E, Liu J Cancer Treat Res. 2023; 186:171-188.

PMID: 37978136 DOI: 10.1007/978-3-031-30065-3_10.


Deubiquitylating Enzymes in Cancer and Immunity.

Ren J, Yu P, Liu S, Li R, Niu X, Chen Y Adv Sci (Weinh). 2023; 10(36):e2303807.

PMID: 37888853 PMC: 10754134. DOI: 10.1002/advs.202303807.


Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer.

Acton A, Placzek W Cancers (Basel). 2023; 15(18).

PMID: 37760451 PMC: 10526511. DOI: 10.3390/cancers15184481.


Mcl-1 deficiency in murine livers leads to nuclear polyploidisation and mitotic errors: Implications for hepatocellular carcinoma.

Clerbaux L, Cordier P, Desboeufs N, Unger K, Leary P, Semere G JHEP Rep. 2023; 5(10):100838.

PMID: 37663116 PMC: 10472239. DOI: 10.1016/j.jhepr.2023.100838.


Targeting MCL-1 protein to treat cancer: opportunities and challenges.

Tantawy S, Timofeeva N, Sarkar A, Gandhi V Front Oncol. 2023; 13:1226289.

PMID: 37601693 PMC: 10436212. DOI: 10.3389/fonc.2023.1226289.


References
1.
Sorensen C, Hansen L, Dziegielewski J, Syljuasen R, Lundin C, Bartek J . The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005; 7(2):195-201. DOI: 10.1038/ncb1212. View

2.
Wolfsperger F, Hogh-Binder S, Schittenhelm J, Psaras T, Ritter V, Bornes L . Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms. Cell Death Dis. 2016; 7:e2039. PMC: 4816183. DOI: 10.1038/cddis.2015.405. View

3.
Perciavalle R, Opferman J . Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol. 2012; 23(1):22-9. PMC: 3532576. DOI: 10.1016/j.tcb.2012.08.011. View

4.
Petermann E, Orta M, Issaeva N, Schultz N, Helleday T . Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell. 2010; 37(4):492-502. PMC: 2958316. DOI: 10.1016/j.molcel.2010.01.021. View

5.
Wilsker D, Petermann E, Helleday T, Bunz F . Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci U S A. 2008; 105(52):20752-7. PMC: 2634938. DOI: 10.1073/pnas.0806917106. View